Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
| Website: | www.regulusrx.com |
| Email: | information@regulusrx.com |
| Main Phone: | +1 858 202-6300 |
| Address: | 10614 Science Center Drive |
| Address 2: | Suite 210 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSD |
| CEO: | Joseph P. Hagan |
| Employees: | 25 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 1.52 | Change $ -0.04 | Change % -2.56 | Tick N/A |
| Bid 1.44 | Bid Size 200.00 | Ask 1.56 | Ask Size 500.00 |
| Open 1.55 | High 1.57 | Low 1.50 | Prev Close 1.56 |
| Last Trade | Volume 61,037 | 52 Wk Hi 17.28 | 52 Wk Low 1.04 |
| Market Cap 13.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 8,750,343.00 | EPS (TTM) -5.54 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 10 |
| Number of Buys | 1 | 10 |
| Number of Sells | 0 | 0 |
| Net Activity | 7695 | 2130745 |
| Last 10 Buys | Shares |
|---|---|
| Timothy Michael Wright | 1,000 |
| William H. Rastetter | 1,000 |
| Joseph P. Hagan | 1,000 |
| Stelios Papadopoulos | 1,000 |
| Daniel R. Chevallard | 1,000 |
| Stelios Papadopoulos | 1,000 |
| Stelios Papadopoulos | 1,000 |
| William H. Rastetter | 1,000 |
| Joseph P. Hagan | 1,000 |
| Mark G. Foletta | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Bruce L.A. Carter | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 1 | 1 | 1 | 1 |
| Mean Target Price Estimate | 1.77 | 1.77 | 1.77 | 1.77 |
| Standard Deviation | 0.77 | 0.77 | 0.77 | 0.77 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 05/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.33 | 2.33 | 2.33 | 2.2 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
